Essam A. Ghazaly
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Journal: Pharmacological reports : PR
Published: May 17, 2023
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Journal: Pharmacological reports : PR
Published: January 23, 2023
Synthesis and Characterization of NUC-7738, an Aryloxy Phosphoramidate of 3'-Deoxyadenosine, as a Potential Anticancer Agent.
Journal: Journal of medicinal chemistry
Published: November 23, 2022
Single Diastereomers of the Clinical Anticancer ProTide Agents NUC-1031 and NUC-3373 Preferentially Target Cancer Stem Cells In Vitro.
Journal: Journal of medicinal chemistry
Published: June 04, 2021
A Phase Ib Open-Label, Dose-Escalation Study of NUC-1031 in Combination with Carboplatin for Recurrent Ovarian Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 10, 2020
A Phase Ib Study of NUC-1031 in Combination with Cisplatin for the First-Line Treatment of Patients with Advanced Biliary Tract Cancer (ABC-08).
Journal: The oncologist
Published: July 01, 2020
Mir142 loss unlocks IDH2R140-dependent leukemogenesis through antagonistic regulation of HOX genes.
Journal: Scientific reports
Published: April 05, 2020
Single Peptide Backbone Surrogate Mutations to Regulate Angiotensin GPCR Subtype Selectivity.
Journal: Chemistry (Weinheim an der Bergstrasse, Germany)
Published: February 20, 2020
Repression of sphingosine kinase (SK)-interacting protein (SKIP) in acute myeloid leukemia diminishes SK activity and its re-expression restores SK function.
Journal: The Journal of biological chemistry
Published: August 15, 2019
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.
Journal: British journal of cancer
Published: March 14, 2018
Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study.
Journal: Haematologica
Published: December 24, 2017
Last Updated: 09/26/2026